PharMerica Co. (NYSE:PMC) has been given an average recommendation of “Hold” by the seven brokerages that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $29.25.
Several brokerages have issued reports on PMC. Zacks Investment Research upgraded shares of PharMerica from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research report on Wednesday, September 27th. ValuEngine upgraded shares of PharMerica from a “hold” rating to a “buy” rating in a research report on Tuesday, October 31st.
In other PharMerica news, CEO Gregory S. Weishar sold 521,089 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $29.25, for a total value of $15,241,853.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.04% of the company’s stock.
PharMerica (NYSE:PMC) opened at $29.25 on Thursday. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.58 and a quick ratio of 1.79. PharMerica has a 12-month low of $22.00 and a 12-month high of $29.50. The stock has a market cap of $910.27, a P/E ratio of 47.95, a price-to-earnings-growth ratio of 1.27 and a beta of 0.82.
PharMerica (NYSE:PMC) last announced its quarterly earnings results on Thursday, November 9th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.49 by ($0.03). PharMerica had a net margin of 0.54% and a return on equity of 2.30%. The business had revenue of $595.10 million during the quarter, compared to analyst estimates of $596.80 million. equities research analysts predict that PharMerica will post 1.92 earnings per share for the current year.
PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals and specialty infusion services to patients outside a hospital setting, and offers the national oncology pharmacy in the United States. Its segments include institutional pharmacy, which provides pharmacy products and services to residents and patients in skilled nursing facilities, nursing centers, assisted living facilities, hospitals and other long-term alternative care settings; specialty infusion services, which provides specialty infusion services focused on providing pharmaceutical products and clinical services to patients in client facilities, hospice and outside of hospital or nursing home settings, and specialty oncology pharmacy, which provides dispensing of oncology drugs, care management and other related services to patients, oncology practices and hospitals.
Receive News & Ratings for PharMerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica and related companies with MarketBeat.com's FREE daily email newsletter.